Maxalt Rapitab

Rizatriptan, the active ingredient in Maxalt Rapitab, is a Triptan presented as an orally disintegrating tablet for oral use. It is indicated for the acute treatment of migraine attacks, with or without aura, in adult patients.

GNH USA supplies Maxalt Rapitab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for global healthcare providers. Our network ensures timely delivery, compliance with local regulations, and access to essential medicines across diverse markets.

Rizatriptan is a Triptan used to treat acute migraine episodes by targeting the serotonergic pathway. - Migraine with aura: provides rapid relief of headache pain, photophobia, phonophobia and nausea associated with attacks. - Migraine without aura: reduces the intensity and duration of headache and associated symptoms. - Acute migraine attack: enables patients to achieve functional recovery within a few hours of dosing.

Rizatriptan may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Taste alteration: a transient metallic or bitter taste. - Nausea: mild to moderate queasiness. - Dizziness: light‑headed sensation, especially on standing.

Serious or Rare Side Effects: - Chest pain or tightness: possible coronary vasospasm. - Serotonin syndrome: agitation, hyperthermia, muscle rigidity when used with other serotonergic drugs. - Severe allergic reaction: rash, swelling, or breathing difficulty.

When prescribing Rizatriptan, clinicians should consider several safety precautions to minimise risk. - Cardiovascular disease: avoid use in patients with uncontrolled coronary artery disease or recent myocardial infarction. - Uncontrolled hypertension: assess blood pressure before initiating therapy. - Concomitant serotonergic drugs: evaluate risk of serotonin syndrome when combined with SSRIs, SNRIs or MAO inhibitors. - History of stroke or transient ischemic attack: use with caution or consider alternative therapy. - Age considerations: safety in patients over 65 has not been fully established; monitor closely. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Rizatriptan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - MAO inhibitors: concurrent use may precipitate severe serotonin syndrome. - Other triptans or ergot derivatives: combined vasoconstrictive effects increase risk of cardiovascular events. - SSRIs, SNRIs, or tricyclic antidepressants: heightened risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance the antihypertensive effect of Rizatriptan. - Oral contraceptives: may increase plasma levels of Rizatriptan, requiring dose adjustment.